PENG - PENG

옵션 체인은 다양한 행사가격과 만기일에 대한 Penguin Solutions의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Penguin Solutions에 대한 시장 심리를 평가합니다..

Penguin Solutions (NASDAQ:PENG) 주식, 옵션 체인

Penguin Solutions

Penguin Solutions Inc is an end-to-end technology company engaged in Intelligent Platform Solutions, Integrated Memory, and Optimized LED business. Its product include Servers, software, OCP HPC & AI system, Racks and Edge. Servers include AMD-based Serves, Intel-based Servers, etc. Software products include Scyld ClusterWare, Scyld Cloud Central, etc. OCP HPC & AI Systems includes OCP Servers & Storage and etc.

Penguin Solutions, Inc. - Ordinary Shares

Dropbox, Telephone and Data Systems And 3 Stocks To Watch Heading Into Friday

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

PENG

목요일(3일) 아침 미국 지수 선물이 하락세를 보이는 가운데, 오늘 투자자들의 관심을 끌 수 있는 주식은 다음과 같다. 어큐이티, RH, 콘아그라, 펭귄 솔루션 및 엑손모빌

목요일 주목해야 할 주식: 어큐이티, RH, 콘아그라, 펭귄 솔루션 및 엑손모빌

Penguin Solutions Inc

Pengram Corp

Flex's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLEX#NYSE">FLEX</a>) short percent of float has risen 18.23% since its last report. The company recently reported that it has 11.14 million shares sold short, which is 4.41% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.67 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Flex Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745596829_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Flex has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Flex's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Flex's peer group average for short interest as a percentage of float is 3.16%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

FLEX

Is the Market Bullish or Bearish on Flex?

Globus Medical's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>) short percent of float has risen 36.6% since its last report. The company recently reported that it has 3.30 million shares sold short, which is 3.21% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.54 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Globus Medical Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745596824_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Globus Medical has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Globus Medical's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Globus Medical's peer group average for short interest as a percentage of float is 4.39%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

GMED

What Does the Market Think About Globus Medical?

In the current market session, PG&amp;E Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCG#NYSE">PCG</a>) share price is at $17.18, after a 1.18% decrease. Over the past month, the stock went up by 1.24%, but over the past year, it actually fell by 0.43%. With good short-term performance like this, and questionable long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio.

<img src="https://www.benzinga.com/files/images/story/2025/1745596820_0.png" alt="Past Year Chart" />

<h3>PG&amp;E P/E Compared to Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 19.58 in the Electric Utilities industry, PG&amp;E Inc. has a lower P/E ratio of 15.95. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1745596820_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

P/E Ratio Insights for PG&E

First Hawaiian's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FHB#NYSE">FHB</a>) short percent of float has risen 4.07% since its last report. The company recently reported that it has 4.99 million shares sold short, which is 6.14% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.71 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>First Hawaiian Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745596819_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for First Hawaiian has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing First Hawaiian's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, First Hawaiian's peer group average for short interest as a percentage of float is 5.24%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into First Hawaiian's Recent Short Interest

Morgan Stanley analyst Joseph Moore maintains NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) with a Overweight and lowers the price target from $162 to $160.

Price Target

Analyst Ratings

NVDA

Morgan Stanley Maintains Overweight on NVIDIA, Lowers Price Target to $160

Keybanc analyst Jason Celino maintains ServiceTitan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTAN#NASDAQ">TTAN</a>) with a Overweight and raises the price target from $120 to $140.

TTAN

Keybanc Maintains Overweight on ServiceTitan, Raises Price Target to $140

Morgan Stanley analyst Joseph Moore maintains Intel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) with a Equal-Weight and lowers the price target from $25 to $23.

INTC

Morgan Stanley Maintains Equal-Weight on Intel, Lowers Price Target to $23

Morgan Stanley analyst Matthew Harrison maintains Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Overweight and raises the price target from $130 to $135.

GILD

Morgan Stanley Maintains Overweight on Gilead Sciences, Raises Price Target to $135

Keybanc analyst Justin Patterson maintains Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) with a Overweight and raises the price target from $185 to $195.

GOOGL

Keybanc Maintains Overweight on Alphabet, Raises Price Target to $195

Morgan Stanley analyst Michael Phillips upgrades RenaissanceRe Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNR#NYSE">RNR</a>) from Equal-Weight to Overweight and raises the price target from $235 to $275.

Upgrades

Morgan Stanley Upgrades RenaissanceRe Holdings to Overweight, Raises Price Target to $275

The U.S. Food and Drug Administration (FDA) on Friday verbally informed that it placed a clinical hold on VYNE Therapeutics Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYNE#NASDAQ">VYNE</a>) Phase 1b study evaluating VYN202 for the treatment of moderate-to-<a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">severe plaque psoriasis</a>.
The clinical hold determination was made following a recent observation of testicular toxicity in dogs from a non-clinical toxicology <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g45005649/vyne-therapeutics-provides-update-on-vyn202-program" rel="noreferrer noopener">study with VYN202</a>.
VYNE has suspended all screening, enrollment, and patient dosing in the Phase 1b trial of VYN202 and intends to work diligently with the FDA to resolve the clinical hold as soon as possible.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44361770/fda-lifts-clinical-hold-on-vtv-therapeutics-phase-3-diabetes-trial-stock-surges" rel="noreferrer noopener">FDA Lifts Clinical Hold On vTv Therapeutics&#8217; Phase 3 Diabetes Trial, Stock Surges</a>
To date, no serious adverse events have been observed in subjects enrolled in the Phase 1b study.
In February, VYNE Therapeutics dosed the first subject in a Phase 1b trial evaluating VYN202 in moderate-to-<a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43810148/vyne-therapeutics-initiates-phase-1b-trial-of-vyn202-a-novel-bd2-selective-oral-bet-inhibitor-in-p" rel="noreferrer noopener">severe plaque psoriasis</a>.
The clinical hold does not apply to VYNE&#8217;s ongoing Phase 2b trial of repibresib gel in nonsegmental vitiligo. Repibresib is a distinct and unique compound from VYN202.
<ul>
<li>Top-line results from the 24-week double-blind, vehicle-controlled portion of the Phase 2b trial are expected mid-2025.</li>
</ul>
In December 2024, VYNE Therapeutics released results from the multiple ascending dose portion of its Phase 1a <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42644632/vyne-therapeutics-reports-positive-top-line-phase-1a-mad-data-for-vyn202-its-novel-bd2-selective-b" rel="noreferrer noopener">SAD/MAD trial of VYN202</a>.
Consistent with Phase 1a SAD results released in <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g40830412/vyne-therapeutics-announces-positive-phase-1a-sad-data-for-vyn202-a-novel-bd2-selective-bet-inhibi" rel="noreferrer noopener">September 2024</a>, VYN202 demonstrated a favorable safety and tolerability profile with no drug-related adverse events historically associated with earlier-generation, less selective BET inhibitors.
As of December&nbsp;31, 2024, VYNE had $61.5 million of cash, cash equivalents, and marketable securities, which is expected to be sufficient to fund its operations into the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44163283/vyne-therapeutics-reports-2024-fourth-quarter-and-year-end-financial-results-and-provides-business" rel="noreferrer noopener">second half of 2026</a>.
Price Action: VYNE stock is down 23.9% at $1.43 at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/45007148/hospital-chain-hca-healthcare-clocks-q1-profit-of-16-billion-on-stronger-volume-says-unchanged-annual-guidance-includes-tariff-impact" target="_blank" rel="noreferrer noopener">HCA Healthcare Shows Strong Pulse In Q1, Keeps 2025 Outlook Healthy</a></li>
</ul>
Photo by Tada Images via Shutterstock

Biotech

Health Care

Movers

General

VYNE

FDA Puts VYNE Therapeutics Early-Stage Psoriasis Study On Hold

Keybanc analyst Matthew Gillmor maintains Encompass Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EHC#NYSE">EHC</a>) with a Overweight and raises the price target from $120 to $122.

Keybanc Maintains Overweight on Encompass Health, Raises Price Target to $122

Nasdaq Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) reported better-than-expected earnings for its <a href="https://www.benzinga.com/quote/NDAQ/earnings">first quarter on Thursday</a>.
The company posted quarterly revenue of $1.24 billion, versus estimates of $1.23 billion. The company's quarterly earnings came in at 79 cents per share, versus estimates of 77 cents per share.
Total revenue was up 11% year-over-year and annual recurring revenue climbed 8% year-over-year to $2.8 billion.
"Nasdaq's first quarter results underscore the resilience of our business model and our ability to deliver growth across our divisions in a rapidly shifting environment," said chair and CEO Adena Friedman.
Nasdaq declared a quarterly dividend of 27 cents per share, payable on June 27 to shareholders of record as of June 13.
In a separate press release, Nasdaq announced that the company and Amazon.com Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) Amazon Web Services (AWS) will introduce a new suite of solutions including infrastructure, software, data management and services that will enable market operators to overcome modernization barriers.
Nasdaq shares fell 0.1% to trade at $74.64 on Friday.
These analysts made changes to their price targets on Nasdaq following earnings announcement.
<ul>
<li>Barclays analyst Benjamin Budish maintained Nasdaq with an Overweight rating and lowered the price target from $86 to $84.</li>
<li>UBS analyst Alex Kramm maintained Nasdaq with a Neutral and raised the price target from $76 to $82.</li>
<li>Keefe, Bruyette &amp; Woods analyst Kyle Voigt maintained the stock with an Outperform rating and raised the price target from $87 to $88..</li>
</ul>
Considering buying NDAQ stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="583" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25115157/image-181-1024x583.png" alt="" class="wp-image-889203" style="width:590px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25115157/image-181-1024x583.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25115157/image-181-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25115157/image-181-768x437.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25115157/image-181.png 1121w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/04/45006630/jim-cramer-onemain-is-too-risky-recommends-buying-reddit">Jim Cramer: OneMain Is &#8216;Too Risky,&#8217; Recommends Buying Reddit</a> </li>
</ul>
Photo via Shutterstock

AMZN

NDAQ

These Analysts Revise Their Forecasts On Nasdaq After Better-Than-Expected Earnings

SES AI Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SES#NYSE">SES</a>) shares are trading higher Friday after the company reported better-than-expected earnings and announced a new <a href="https://www.benzinga.com//node/44995431">share repurchase program.</a>
What To Know: SES reported a loss of 4 cents per share, beating analysts&#8217; estimate of 6-cent loss. The company also reported record revenue of $5.8 million.
Looking ahead, the company affirmed its 2025 sales guidance of $15 million to $25 million, versus analysts&#8217; estimate of $22 million. Additionally, It expects to exit 2025 with more than $200 million in liquidity.
The company authorized a $30 million share repurchase program.
Qichao Hu, Founder and CEO of SES AI, said, &#8220;Our Board&#8217;s approval of this share repurchase program reflects our confidence in SES AI&#8217;s revenue projections for the year, the affirmation of our previously issued 2025 full year revenue&nbsp;guidance, and the expectation that we will exit 2025 with above&nbsp;$200 million&nbsp;in liquidity. We believe share repurchases are an effective capital allocation tool, providing a compelling opportunity to enhance shareholder value. The potential allocation of capital in an accretive fashion does not sacrifice our liquidity runway.&#8221;
See Also: <a href="https://www.benzinga.com/insights/news/25/04/45009839/100-invested-in-this-stock-10-years-ago-would-be-worth-this-much-today">$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today</a>
SES Price Action: At the time of writing, SES stock is trading 26.6% higher at $1.10, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro.</a>
Image: This illustration was generated using artificial intelligence via Midjourney.

What's Going On With SES AI Shares Friday?

Keefe, Bruyette &amp; Woods analyst Christopher Mcgratty maintains Webster Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WBS#NYSE">WBS</a>) with a Outperform and lowers the price target from $70 to $65.

Keefe, Bruyette & Woods Maintains Outperform on Webster Financial, Lowers Price Target to $65

<a target="_blank" href="https://www.benzinga.com/topic/autonomous-driving" rel="noreferrer noopener">Chinese autonomous driving</a> company Pony AI Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>) on Friday shared plans to develop autonomous driving technology in partnership with Tencent Holding (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCEHY#OTC">TCEHY</a>) Tencent Cloud and deploy robotaxi services on Tencent&#8217;s WeChat and other applications.
The deal will include cooperation in cloud services, map data, information security, and intelligent cockpit ecosystems, CNBC <a target="_blank" href="https://www.cnbc.com/2025/04/25/ponyai-teams-up-with-tencent-for-robotaxi-services-on-wechat-other-apps.html" rel="noreferrer noopener">reported</a> Friday, citing the company press release.
The companies will also integrate Pony.ai&#8217;s robotaxi ride-hailing services into Tencent&#8217;s WeChat app and other applications, such as Tencent Maps.&nbsp;
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/25/04/44978234/intel-autonomous-driving-firm-mobileye-reaffirms-2025-outlook-after-record-q1-growth-in-system-shipments-and-design-wins" rel="noreferrer noopener">Intel Autonomous Driving Firm Mobileye Reaffirms 2025 Outlook After Record Q1 Growth</a>
Pony.ai CEO James Peng told CNBC on Friday at the Shanghai Auto Show that both companies had been discussing a deal for some time.
Peng also hinted at the possibility of WeChat app users booking Pony.ai robotaxi rides straight through their app.
The companies will also collaborate on developing, testing, and operating Robotaxis, particularly in L4-level autonomous driving. Pony.ai showcased its L4, seventh-generation robotaxi solution on Wednesday at the Shanghai Auto Show.
Separately, Pony.ai announced that Hesai Group&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSAI#NASDAQ">HSAI</a>) lidar will power its <a target="_blank" href="https://www.benzinga.com/25/04/44993180/pony-ai-shares-surge-after-hesai-lidar-partnership-announcement-whats-going-on" rel="noreferrer noopener">new robotaxi fleet</a>.
In April, Pony.ai <a target="_blank" href="https://www.benzinga.com/25/04/44627035/pony-ai-teams-up-with-luxembourg-transit-giant-to-launch-level-4-autonomous-vehicle-trials" rel="noreferrer noopener">won approval to</a> begin Level 4 robotaxi testing in Luxembourg with local transit partner Emile Weber.
The company has testing permits in China, the U.S., South Korea and Luxembourg.
In March, Pony.ai&nbsp;launched a paid, fully driverless robotaxis in Shenzhen&#8217;s key Nanshan business district. The company expanded commercial operations to connect Nanshan with its existing service zone in Baoan District.
In U.S., Volkswagen (OTC:<a class="ticker" href="https://www.benzinga.com/stock/VWAGY#OTC">VWAGY</a>) and&nbsp;Uber Technologies, Inc&nbsp;announced on Thursday <a target="_blank" href="https://www.benzinga.com/news/25/04/44988070/autonomous-ride-hailing-just-got-real-vw-and-uber-reveal-first-us-city" rel="noreferrer noopener">a collaboration to</a> deploy an all-electric, fully autonomous ID. Buzz AD vehicles within multiple U.S. markets, starting in Los Angeles&nbsp;over the next decade.
Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) tweeted&nbsp;Wednesday that it has started testing its autonomous ride-hail service with Austin and the Bay Area employees ahead of its planned robotaxi launch this summer.
Price Action: PONY stock is down 9.51% to $6.85 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44934176/rivian-taps-ai-expert-aidan-gomez-to-drive-innovation-advanced-technology-integration" target="_blank" rel="noreferrer noopener">Tesla Rival Rivian Taps AI Expert Aidan Gomez To Drive Innovation</a></li>
</ul>
Photo by Tada Images via Shutterstock

Media

HSAI

PONY

TCEHY

TSLA

VWAGY

Pony.ai And Tencent Partner On L4 Robotaxis, Expand China's Self-Driving Future

Keefe, Bruyette &amp; Woods analyst Wood Lay maintains Third Coast Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBX#NASDAQ">TCBX</a>) with a Market Perform and lowers the price target from $39 to $36.

TCBX

Keefe, Bruyette & Woods Maintains Market Perform on Third Coast Bancshares, Lowers Price Target to $36

<a href="https://www.statnews.com/2025/04/25/akeso-wins-chinese-approval-for-cancer-drug-ivonescimab-keytruda-rival/" title="https://www.statnews.com/2025/04/25/akeso-wins-chinese-approval-for-cancer-drug-ivonescimab-keytruda-rival/">https://www.statnews.com/2025/04/25/akeso-wins-chinese-approval-for-cancer-drug-ivonescimab-keytruda-rival/</a>

Global

SMMT

'Akeso Wins Chinese Approval For Cancer Drug Positioned To Rival Merck's Keytruda; Company Discloses Early Data Hinting At A Survival Benefit' - STAT News

Keefe, Bruyette &amp; Woods analyst Aidan Hall maintains SEI Investments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEIC#NASDAQ">SEIC</a>) with a Market Perform and raises the price target from $80 to $84.

SEIC

Keefe, Bruyette & Woods Maintains Market Perform on SEI Investments, Raises Price Target to $84

Keefe, Bruyette &amp; Woods analyst Christopher Mcgratty maintains Old Second Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSBC#NASDAQ">OSBC</a>) with a Outperform and lowers the price target from $24 to $22.

OSBC

Keefe, Bruyette & Woods Maintains Outperform on Old Second Bancorp, Lowers Price Target to $22

Small Cap

Press Releases

Penguin Solutions Reports Q1 Fiscal 2025 Financial Results

Penguin Solutions Signs AI Data Center Collaboration Agreement with SK Telecom and SK hynix

SMART Modular Add-In Cards Now Listed on CXL Consortium Integrators' List

Cree LED Advances Horticulture Lighting with Launch of XLamp XP-L Photo Red S Line LEDs

Penguin Solutions Expands Its AI Infrastructure Management Software Platform and Introduces Robust AI Optimization Service

Penguin Solutions Announces Second Quarter Fiscal 2025 Financial Conference Call

Penguin Solutions, Inc. Announces Proposed Redomiciliation to the United States

SMART Modular Technologies Introduces its Non-Volatile CXL E3.S Memory Module

Penguin Solutions Reports Q2 Fiscal 2025 Financial Results

SMART Modular Expands CXL Offerings with Addition of E3.S 2T 128GB CMM to CXL Consortium's Integrator List

Allegro MicroSystems, Inc. - Common Stock

Allegro Microsystems

Ambarella

Alpha and Omega Semiconductor Limited - Common Shares

Alpha & Omega

Blaize Holdings

CEVA

Canadian Solar

Diodes

Himax Technologies, Inc. - American depositary shares, each of which represents two ordinary shares.

Himax Techs

ChipMOS TECHNOLOGIES INC. - American Depositary Shares

ChipMOS TECHNOLOGIES

indie Semiconductor, Inc. - Class A Common Stock

Indie Semiconductor

JinkoSolar Holding Company Limited American Depositary Shares (each representing 4 Common Shares)

JinkoSolar Holding Co

SEALSQ

MaxLinear

Navitas Semiconductor Corporation - Common Stock

Navitas Semiconductor

Impinj

Power Integrations

Rigetti Computing

Silicon Motion Technology Corporation - American Depositary Shares, each representing four ordinary shares

Comments

Penguin Solutions

Penguin Solutions (PENG) 옵션

Penguin Solutions (NASDAQ:PENG) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌